Identification of a WT1 protein-derived peptide, WT1187, as a HLA-A*0206-restricted, WT1-specific CTL epitope

Microbiology and Immunology

Volumn 52, Issue 11, 2008, Pages 551-558

  Li, Zheyu ^a   Oka, Yoshihiro ^a   Tsuboi, Akihiro ^a   Fujiki, Fumihiro ^a   Harada, Yukie ^a   Nakajima, Hiroko ^a   Masuda, Tomoki ^a   Fukuda, Yoko ^a   Kawakatsu, Mai ^a   Morimoto, Soyoko ^a   Katagiri, Takamasa ^a   Tatsumi, Naoya ^a   Hosen, Naoki ^a   Shirakata, Toshiaki ^a   Nishida, Sumiyuki ^a   Kawakami, Yutaka ^b   Udaka, Keiko ^c   Kawase, Ichiro ^a   Oji, Yusuke ^a   Sugiyama, Haruo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Cancer; HLA A*0206; Vaccine; WT1

Indexed keywords

HLA A ANTIGEN; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; WT1 PROTEIN; WT1187 PROTEIN; EPITOPE; HLA A*0206 ANTIGEN; HLA-A*0206 ANTIGEN; OLIGOPEPTIDE;

ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; LEUKEMIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; CYTOTOXICITY TEST; EPITOPE MAPPING; IMMUNOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; GENES, WILMS TUMOR; HLA-A ANTIGENS; HUMANS; OLIGOPEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; WT1 PROTEINS;

EID: 58249088449     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2008.00069.x     Document Type: Article

References (45)

1. Call K.M., Glaser T., Ito C.Y., Buckler A.J., Pelletier J., Haber D.A., Rose E.A., Kral A., Yeger H., Lewis W.H., et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11Wilms' tumor locus. Cell 60: 509-20.
2. Gessler M., Poustka A., Cavenee W., Neve R.L., Orkin S.H., Bruns G.A. (1990) Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 343: 774-8.
3. Drummond I.A., Madden S.L., Rohwer-Nutter P., Bell G.I., Sukhatme V.P., Rauscher F.J., 3rd. (1992) Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 257: 674-8.
4. Englert C., Hou X., Maheswaran S., Bennett P., Ngwu C., Re G. G., Garvin A.J., Rosner M. R., Haber D.A. (1995) WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. Embo J 14: 4662-75.
5. Hewitt S. M., Hamada S., McDonnell T.J., Rauscher F.J., 3rd, Saunders G.F. (1995) Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res 55: 5386-9.
6. Bergmann L., Miething C., Maurer U., Brieger J., Karakas T., Weidmann E., Hoelzer D. (1997) High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 90: 1217-25.
7. Inoue K., Ogawa H., Sonoda Y., Kimura T., Sakabe H., Oka Y., Miyake S., Tamaki H., Oji Y., Yamagami T., Tatekawa T., Soma T., Kishimoto T., Sugiyama H. (1997) Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89: 1405-12.
8. Inoue K., Sugiyama H., Ogawa H., Nakagawa M., Yamagami T., Miwa H., Kita K., Hiraoka A., Masaoka T., Nasu K., et al. (1994) WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84: 3071-9.
9. Inoue K., Tamaki H., Ogawa H., Oka Y., Soma T., Tatekawa T., Oji Y., Tsuboi A., Kim E.H., Kawakami M., Akiyama T., Kishimoto T., Sugiyama H. (1998)Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 91: 2969-76.
10. Menssen H. D., Renkl H.J., Rodeck U., Maurer J., Notter M., Schwartz S., Reinhardt R., Thiel E. (1995) Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 9: 1060-7.
11. Tsuboi A., Oka Y., Ogawa H., Elisseeva O.A., Tamaki H., Oji Y., Kim E.H., Soma T., Tatekawa T., Kawakami M., Kishimoto T., Sugiyama H. (1999) Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk Res 23: 499-505.
12. Yamagami T., Sugiyama H., Inoue K., Ogawa H., Tatekawa T., Hirata M., Kudoh T., Akiyama T., Murakami A., Maekawa T. (1996) Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 87: 2878-84.
13. Oji Y., Miyoshi S., Maeda H., Hayashi S., Tamaki H., Nakatsuka S., Yao M., Takahashi E., Nakano Y., Hirabayashi H., Shintani Y., Oka Y., Tsuboi A., Hosen N., Asada M., Fujioka T., Murakami M., Kanato K., Motomura M., Kim E.H., Kawakami M., Ikegame K., Ogawa H., Aozasa K., Kawase I., Sugiyama H. (2002) Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int J Cancer 100: 297-303.
14. Oji Y., Ogawa H., Tamaki H., Oka Y., Tsuboi A., Kim E.H., Soma T., Tatekawa T., Kawakami M., Asada M., Kishimoto T., Sugiyama H. (1999) Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 90: 194-204.
15. Oji Y., Yamamoto H., Nomura M., Nakano Y., Ikeba A., Nakatsuka S., Abeno S., Kiyotoh E., Jomgeow T., Sekimoto M., Nezu R., Yoshikawa Y., Inoue Y., Hosen N., Kawakami M., Tsuboi A., Oka Y., Ogawa H., Souda S., Aozasa K., Monden M., Sugiyama H. (2003) Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci 94: 712-7.
16. Oji Y., Yano M., Nakano Y., Abeno S., Nakatsuka S., Ikeba A., Yasuda T., Fujiwara Y., Takiguchi S., Yamamoto H., Fujita S., Kanato K., Ito K., Jomgeow T., Kawakami M., Tsuboi A., Shirakata T., Nishida S., Hosen N., Oka Y., Aozasa K., Monden M., Sugiyama H. (2004) Overexpression of the Wilms' tumor gene WT1 in esophageal cancer. Anticancer Res 24: 3103-8.
17. Nakajima H., Kawasaki K., Oka Y., Tsuboi A., Kawakami M., Ikegame K., Hoshida Y., Fujiki F., Nakano A., Masuda T., Wu F., Taniguchi Y., Yoshihara S., Elisseeva O.A., Oji Y., Ogawa H., Azuma I., Kawase I., Aozasa K., Sugiyama H. (2004) WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone. Cancer Immunol Immunother 53: 617-24.
18. Oka Y., Udaka K., Tsuboi A., Elisseeva O.A., Ogawa H., Aozasa K., Kishimoto T., Sugiyama H. (2000) Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 164: 1873-80.
19. Gao L., Bellantuono I., Elsasser A., Marley S. B., Gordon M. Y., Goldman J. M., Stauss H.J. (2000) Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95: 2198-203.
20. Li Z., Oka Y., Tsuboi A., Masuda T., Tatsumi N., Kawakami M., Fujioka T., Sakaguchi N., Nakajima H., Fujiki F., Udaka K., Oji Y., Kawase I., Sugiyama H. (2005) WT1(235), a ninemer peptide derived from Wilms' tumor gene product, is a candidate peptide for the vaccination of HLA-A*0201-positive patients with hematopoietic malignancies. Int J Hematol 82: 458-9.
21. Ohminami H., Yasukawa M., Fujita S. (2000) HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95: 286-93.
22. Oka Y., Elisseeva O.A., Tsuboi A., Ogawa H., Tamaki H., Li H., Oji Y., Kim E.H., Soma T., Asada M., Ueda K., Maruya E., Saji H., Kishimoto T., Udaka K., Sugiyama H. (2000) Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 51: 99-107.
23. Oka Y., Tsuboi A., Elisseeva O.A., Nakajima H., Fujiki F., Kawakami M., Shirakata T., Nishida S., Hosen N., Oji Y., Kawase I., Sugiyama H. (2007) WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers. ScientificWorldJournal 7: 649-65.
24. Oka Y., Tsuboi A., Murakami M., Hirai M., Tominaga N., Nakajima H., Elisseeva O.A., Masuda T., Nakano A., Kawakami M., Oji Y., Ikegame K., Hosen N., Udaka K., Yasukawa M., Ogawa H., Kawase I., Sugiyama H. (2003)Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 78: 56-61.
25. Oka Y., Tsuboi A., Taguchi T., Osaki T., Kyo T., Nakajima H., Elisseeva O.A., Oji Y., Kawakami M., Ikegame K., Hosen N., Yoshihara S., Wu F., Fujiki F., Murakami M., Masuda T., Nishida S., Shirakata T., Nakatsuka S., Sasaki A., Udaka K., Dohy H., Aozasa K., Noguchi S., Kawase I., Sugiyama H. (2004) Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 101: 13885-90.
26. Scheibenbogen C., Letsch A., Thiel E., Schmittel A., Mailaender V., Baerwolf S., Nagorsen D., Keilholz U. (2002) CD8T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 100: 2132-7.
27. Tsuboi A., Oka Y., Osaki T., Kumagai T., Tachibana I., Hayashi S., Murakami M., Nakajima H., Elisseeva O.A., Fei W., Masuda T., Yasukawa M., Oji Y., Kawakami M., Hosen N., Ikegame K., Yoshihara S., Udaka K., Nakatsuka S., Aozasa K., Kawase I., Sugiyama H. (2004) WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases. Microbiol Immunol 48: 175-84.
28. Luka J., Lindahl T., Klein G. (1978) Purification of the Epstein-Barr virus-determined nuclear antigen from Epstein-Barr virus-transformed human lymphoid cell lines. J Virol 27: 604-11.
29. Ohnishi M., Sakurai T., Heike Y., Yamazaki R., Kanda Y., Takaue Y., Mizoguchi H., Kawakami Y. (2005) Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope. Br J Haematol 131: 472-9.
30. Dauer M., Schad K., Herten J., Junkmann J., Bauer C., Kiefl R., Endres S., Eigler A. (2005) FastDC derived from human monocytes within 48 h effectively prime tumor antigen-specific cytotoxic T cells. J Immunol Methods 302: 145-55.
31. + T-cell clones for immunotherapy from the naive repertoire. J Immunol Methods 310: 40-52.
32. Visseren M.J., van Elsas A., Van Der Voort E. I., Ressing M. E., Kast W. M., Schrier P. I., Melief C.J. (1995) CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol 154: 3991-8.
33. Hladik F., Desbien A., Lang J., Wang L., Ding Y., Holte S., Wilson A., Xu Y., Moerbe M., Schmechel S., McElrath M.J. (2003) Most highly exposed seronegative men lack HIV-1-specific, IFN-gamma-secreting T cells. J Immunol 171: 2671-83.
34. Sudo T., Kamikawaji N., Kimura A., Date Y., Savoie C.J., Nakashima H., Furuichi E., Kuhara S., Sasazuki T. (1995) Differences in MHC class I self peptide repertoires among HLA-A2 subtypes. J Immunol 155: 4749-56.
35. Browning M., Krausa P. (1996) Genetic diversity of HLA-A2: evolutionary and functional significance. Immunol Today 17: 165-70.
36. Ellis J. M., Henson V., Slack R., Ng J., Hartzman R.J., Katovich Hurley C. (2000) Frequencies of HLA-A2 alleles in five U.S. population groups. Predominance of A*02011 and identification of HLA-A*0231. Hum Immunol 61: 334-40.
37. Fernandez-Vina M.A., Falco M., Sun Y., Stastny P. (1992) DNA typing for HLA class I alleles: I. Subsets of HLA-A2 and of -A28. Hum Immunol 33: 163-73.
38. Sette A., Sidney J. (1999) Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50: 201-12.
39. Kimura A., Date Y., Sasazuki T. (1994) DNA typing of HLA-A gene [in Japanese]. Transplantation Now 7: 10-22.
40. Park M.H., Whang D.H., Kang S.J., Han K.S. (2000) HLA-A*02 allele frequencies and haplotypic associations in Koreans. Tissue Antigens 55: 250-6.
41. Oka Y., Tsuboi A., Kawakami M., Elisseeva O.A., Nakajima H., Udaka K., Kawase I., Oji Y., Sugiyama H. (2006) Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Curr Med Chem 13: 2345-52.
42. Tsuboi A., Oka Y., Udaka K., Murakami M., Masuda T., Nakano A., Nakajima H., Yasukawa M., Hiraki A., Oji Y., Kawakami M., Hosen N., Fujioka T., Wu F., Taniguchi Y., Nishida S., Asada M., Ogawa H., Kawase I., Sugiyama H. (2002) Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-merWT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 51: 614-20.
43. Fujiki F., Oka Y., Tsuboi A., Kawakami M., Kawakatsu M., Nakajima H., Elisseeva O.A., Harada Y., Ito K., Li Z., Tatsumi N., Sakaguchi N., Fujioka T., Masuda T., Yasukawa M., Udaka K., Kawase I., Oji Y., Sugiyama H. (2007) Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1* 0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes. J Immunother 30: 282-93.
44. Iiyama T., Udaka K., Takeda S., Takeuchi T., Adachi Y.C., Ohtsuki Y., Tsuboi A., Nakatsuka S., Elisseeva O.A., Oji Y., Kawakami M., Nakajima H., Nishida S., Shirakata T., Oka Y., Shuin T., Sugiyama H. (2007) WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 51: 519-30.
45. Kawakami M., Oka Y., Tsuboi A., Harada Y., Elisseeva O.A., Furukawa Y., Tsukaguchi M., Shirakata T., Nishida S., Nakajima H., Morita S., Sakamoto J., Kawase I., Oji Y., Sugiyama H. (2007) Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia. Int J Hematol 85: 426-9.